Minori Rosales

Chief Tech/Sci/R&D Officer at COMPASS THERAPEUTICS, INC.

61 year

Health Technology

Consumer Services

Profile

Minori Rosales is a Senior Vice President & Head-Clinical Development at Compass Therapeutics, Inc. She previously worked as a Vice President at MedImmune LLC from 2017 to 2018, as a Vice President-Clinical Research at MacroGenics, Inc. from 2018 to 2022, and as a Chief Development Officer at Sesen Bio, Inc. from 2022 to 2023.
Rosales holds a doctorate degree from Yamaguchi University and Kansai Medical University.

Minori Rosales active positions

Companies	Position	Start
COMPASS THERAPEUTICS, INC.	Chief Tech/Sci/R&D Officer	30/04/2023

All active positions of Minori Rosales

Former positions of Minori Rosales

Companies	Position	End
CARISMA THERAPEUTICS, INC.	Corporate Officer/Principal	30/04/2023
MACROGENICS, INC.	Chief Tech/Sci/R&D Officer	31/12/2021
MedImmune LLC MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD.	Corporate Officer/Principal	31/12/2017

See the detail of Minori Rosales's experience

Training of Minori Rosales

Yamaguchi University	Doctorate Degree
Kansai Medical University	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Minori Rosales's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
MACROGENICS, INC.	Health Technology
COMPASS THERAPEUTICS, INC.	Health Technology

Private companies	2
MedImmune LLC MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD.	Health Technology
Sesen Bio, Inc. Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.	Health Technology